ASCO 2017 Prostate Cancer - Results from #20

Viewing 21-40 of 85 articles

ASCO 2017: Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC)

ASCO 2017: A secondary analysis of PSA response in NRG Oncology/RTOG 9902: A phase III trial of adjuvant chemotherapy with androgen suppression and radiation for high-risk prostate cancer

ASCO 2017: Identification of low prostate-specific antigen, high Gleason prostate cancer as a unique hormone-resistant entity with poor survival: A contemporary analysis of 640,000 patients

ASCO 2017: PSA doubling time and proximal PSA value predict metastasis-free survival in men with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy

ASCO 2017: Association of risk of clinical recurrence and prostate cancer death with a 17-gene genomic prostate score value

ASCO 2017: Development and external validation of a novel risk score to identify insignificant prostate cancer

ASCO 2017: Emerging Biomarkers of Chemotherapy Resistance

ASCO 2017: Clinical Implications of Genomic Sequencing in Prostate Cancer

ASCO 2017: Serum androgens and survival in metastatic castration resistant prostate cancer patients treated with docetaxel and prednisone: Results from CALGB 90401 (Alliance)

ASCO 2017: History of PSA Screening on Prostate Cancer Aggressiveness

ASCO 2017: P53 status in primary tumor predicts efficacy of first-line abiraterone and enzalutamide in castration-resistant prostate cancer patients

ASCO 2017: A 17-gene panel for prediction of adverse surgical pathology in the setting of MRI-guided prostate biopsy

ASCO 2017: Association of loss of tumor suppressor ZFP36 with lethal prostate cancer

ASCO 2017: Association of androgen receptor status in plasma DNA with outcome on enzalutamide or abiraterone or castration resistant prostate cancer

ASCO 2017: Ten-year overall and prostate cancer specific mortality in high-risk patients after high-dose-rate brachytherapy combined with external beam radiation therapy (HDR-BT/EBRT) compared with EBRT alone

ASCO 2017: Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer

ASCO 2017: Whole blood androgen receptor variant expression and overall survival in metastatic castrate resistant prostate cancer

ASCO 2017: The plasma lipidome in castration-resistant prostate cancer

ASCO 2017: Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC)

ASCO 2017: Incidence of intrathoracic metastases detected by 68Ga-PSMA-11 PET in early stage prostate cancer

1
2
3
4
5